HALOZYME THERAPEUTICS, INC. Revenues
HALOZYME THERAPEUTICS, INC. (HALO) reported Revenues of $121.70 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-02-23.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2021-02-23
- HALOZYME THERAPEUTICS, INC. revenues for the quarter ending 2020-12-31 was $121.70M, a 126.78% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. revenues for the quarter ending 2020-09-30 was $65.32M, a 41.28% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. revenues for the quarter ending 2020-06-30 was $55.22M, a 41.06% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. revenues for the quarter ending 2020-03-31 was $25.35M, a 55.48% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. revenues for fiscal 2018 was $151.86M, a 52.04% decline from fiscal 2017.
- HALOZYME THERAPEUTICS, INC. revenues for fiscal 2017 was $316.61M, a 115.84% increase from fiscal 2016.
- HALOZYME THERAPEUTICS, INC. revenues for fiscal 2016 was $146.69M, a 8.61% increase from fiscal 2015.
- HALOZYME THERAPEUTICS, INC. revenues for fiscal 2015 was $135.06M, a 79.28% increase from fiscal 2014.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $121.70M 10-K · filed 2021-02-23 | $187.02M derived: sum of 2 quarters · filed 2021-02-23 | $242.24M derived: sum of 3 quarters · filed 2021-02-23 | $267.59M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2020-09-30 | $65.32M 10-K · filed 2021-02-23 | $120.54M derived: sum of 2 quarters · filed 2021-02-23 | $145.89M derived: sum of 3 quarters · filed 2021-02-23 | $199.56M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2020-06-30 | $55.22M 10-K · filed 2021-02-23 | $80.58M derived: sum of 2 quarters · filed 2021-02-23 | $134.24M derived: sum of 3 quarters · filed 2021-02-23 | $180.47M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2020-03-31 | $25.35M 10-K · filed 2021-02-23 | $79.02M derived: sum of 2 quarters · filed 2021-02-23 | $125.25M derived: sum of 3 quarters · filed 2021-02-23 | $164.40M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-12-31 | $53.66M 10-K · filed 2021-02-23 | $99.89M derived: sum of 2 quarters · filed 2021-02-23 | $139.04M derived: sum of 3 quarters · filed 2021-02-23 | $195.99M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-09-30 | $46.23M 10-K · filed 2021-02-23 | $85.38M derived: sum of 2 quarters · filed 2021-02-23 | $142.33M derived: sum of 3 quarters · filed 2021-02-23 | $202.56M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-06-30 | $39.15M 10-K · filed 2021-02-23 | $96.10M derived: sum of 2 quarters · filed 2021-02-23 | $156.33M derived: sum of 3 quarters · filed 2021-02-23 | $181.88M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-03-31 | $56.95M 10-K · filed 2021-02-23 | $117.18M derived: sum of 2 quarters · filed 2021-02-23 | $142.74M derived: sum of 3 quarters · filed 2021-02-23 | $177.94M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2018-12-31 | $60.23M 10-K · filed 2020-02-24 | $85.79M derived: sum of 2 quarters · filed 2020-02-24 | $120.99M derived: sum of 3 quarters · filed 2020-02-24 | $151.86M 10-K · filed 2019-02-21 | ||||
| 2018-09-30 | $25.56M 10-K · filed 2020-02-24 | $60.76M derived: sum of 2 quarters · filed 2020-02-24 | $91.63M 10-Q · filed 2018-11-06 | $281.19M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-06-30 | $35.20M 10-K · filed 2020-02-24 | $66.07M 10-Q · filed 2018-08-07 | $255.64M derived: sum of 3 quarters · filed 2020-02-24 | $319.37M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-03-31 | $30.87M 10-K · filed 2020-02-24 | $220.44M derived: sum of 2 quarters · filed 2020-02-24 | $284.17M derived: sum of 3 quarters · filed 2020-02-24 | $317.92M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $189.56M 10-K · filed 2019-02-21 | $253.29M derived: sum of 2 quarters · filed 2019-02-21 | $287.05M derived: sum of 3 quarters · filed 2019-02-21 | $316.61M 10-K · filed 2019-02-21 | ||||
| 2017-09-30 | $63.73M 10-K · filed 2019-02-21 | $97.48M derived: sum of 2 quarters · filed 2019-02-21 | $127.05M 10-Q · filed 2018-11-06 | $166.05M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2017-06-30 | $33.75M 10-K · filed 2019-02-21 | $63.32M 10-Q · filed 2018-08-07 | $102.32M derived: sum of 3 quarters · filed 2019-02-21 | $134.17M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2017-03-31 | $29.57M 10-K · filed 2019-02-21 | $68.57M derived: sum of 2 quarters · filed 2019-02-21 | $100.42M derived: sum of 3 quarters · filed 2019-02-21 | $133.76M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2016-12-31 | $39.00M 10-K · filed 2018-02-20 | $52.23M 10-K · filed 2017-02-28 | $70.86M derived: sum of 2 quarters · filed 2018-02-20 | $104.19M derived: sum of 3 quarters · filed 2018-02-20 | $146.69M 10-K · filed 2019-02-21 | |||
| 2016-09-30 | $31.85M 10-K · filed 2018-02-20 | $65.19M derived: sum of 2 quarters · filed 2018-02-20 | $107.69M 10-Q · filed 2017-11-07 | $146.69M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-06-30 | $33.34M 10-K · filed 2018-02-20 | $75.83M 10-Q · filed 2017-08-08 | $114.84M derived: sum of 3 quarters · filed 2018-02-20 | $146.69M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-03-31 | $42.50M 10-K · filed 2018-02-20 | $81.50M derived: sum of 2 quarters · filed 2018-02-20 | $113.36M derived: sum of 3 quarters · filed 2018-02-20 | $146.69M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2015-12-31 | $39.00M 10-K · filed 2017-02-28 | $52.23M 10-K · filed 2016-02-29 | $70.86M derived: sum of 2 quarters · filed 2017-02-28 | $104.19M derived: sum of 3 quarters · filed 2017-02-28 | $135.06M 10-K · filed 2018-02-20 | |||
| 2015-09-30 | $31.85M 10-K · filed 2017-02-28 | $20.78M 10-Q · filed 2015-11-09 | $65.19M derived: sum of 2 quarters · filed 2017-02-28 | $82.83M 10-Q · filed 2016-11-07 | $138.06M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | $33.34M 10-K · filed 2017-02-28 | $43.38M 10-Q · filed 2015-08-10 | $62.05M 10-Q · filed 2016-08-09 | $106.21M derived: sum of 3 quarters · filed 2017-02-28 | $120.82M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $42.50M 10-K · filed 2017-02-28 | $18.67M 10-Q · filed 2015-05-11 | $72.88M derived: sum of 2 quarters · filed 2017-02-28 | $87.48M derived: sum of 3 quarters · filed 2017-02-28 | $105.87M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $30.38M 10-K · filed 2016-02-29 | $44.98M derived: sum of 2 quarters · filed 2016-02-29 | $63.37M derived: sum of 3 quarters · filed 2016-02-29 | $75.33M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $14.61M 10-K · filed 2016-02-29 | $32.99M derived: sum of 2 quarters · filed 2016-02-29 | $44.96M 10-Q · filed 2015-11-09 | $57.46M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $18.39M 10-K · filed 2016-02-29 | $30.35M 10-Q · filed 2015-08-10 | $42.85M derived: sum of 3 quarters · filed 2016-02-29 | $58.86M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $11.97M 10-K · filed 2016-02-29 | $24.46M derived: sum of 2 quarters · filed 2016-02-29 | $40.48M derived: sum of 3 quarters · filed 2016-02-29 | $54.93M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $12.50M 10-K · filed 2015-03-02 | $12.50M 10-K · filed 2014-02-28 | $28.51M derived: sum of 2 quarters · filed 2015-03-02 | $42.97M derived: sum of 3 quarters · filed 2015-03-02 | $54.80M 10-K · filed 2016-02-29 | $54.80M 10-K · filed 2014-02-28 | ||
| 2013-09-30 | $16.01M 10-K · filed 2015-03-02 | $16.01M 10-Q · filed 2013-11-08 | $30.47M derived: sum of 2 quarters · filed 2015-03-02 | $42.30M 10-Q · filed 2014-11-10 | $42.30M 10-Q · filed 2013-11-08 | $64.09M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $14.45M 10-K · filed 2015-03-02 | $14.45M 10-Q · filed 2013-08-07 | $26.29M 10-Q · filed 2014-08-11 | $26.29M 10-Q · filed 2013-08-07 | $48.08M derived: sum of 3 quarters · filed 2015-03-02 | $53.41M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $11.83M 10-K · filed 2015-03-02 | $11.83M 10-Q · filed 2013-05-08 | $33.63M derived: sum of 2 quarters · filed 2015-03-02 | $38.96M derived: sum of 3 quarters · filed 2015-03-02 | $46.72M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $21.79M 10-K · filed 2014-02-28 | $27.13M derived: sum of 2 quarters · filed 2014-02-28 | $34.89M derived: sum of 3 quarters · filed 2014-02-28 | $42.33M 10-K · filed 2015-03-02 | $42.33M 10-K · filed 2013-03-01 | |||
| 2012-09-30 | $5.33M 10-K · filed 2014-02-28 | $13.09M derived: sum of 2 quarters · filed 2014-02-28 | $20.53M 10-Q · filed 2013-11-08 | $22.94M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-06-30 | $7.76M 10-K · filed 2014-02-28 | $15.20M 10-Q · filed 2013-08-07 | $17.61M derived: sum of 3 quarters · filed 2014-02-28 | $40.55M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-03-31 | $7.44M 10-K · filed 2014-02-28 | $9.85M derived: sum of 2 quarters · filed 2014-02-28 | $32.79M derived: sum of 3 quarters · filed 2014-02-28 | $55.98M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2011-12-31 | $2.41M 10-K · filed 2013-03-01 | $25.35M derived: sum of 2 quarters · filed 2013-03-01 | $48.54M derived: sum of 3 quarters · filed 2013-03-01 | $56.09M 10-K · filed 2014-02-28 | ||||
| 2011-09-30 | $22.94M 10-K · filed 2013-03-01 | $46.13M derived: sum of 2 quarters · filed 2013-03-01 | $53.68M 10-Q · filed 2012-11-08 | $57.25M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-06-30 | $23.19M 10-K · filed 2013-03-01 | $30.73M 10-Q · filed 2012-08-09 | $34.31M derived: sum of 3 quarters · filed 2013-03-01 | $37.70M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-03-31 | $7.54M 10-K · filed 2013-03-01 | $11.12M derived: sum of 2 quarters · filed 2013-03-01 | $14.51M derived: sum of 3 quarters · filed 2013-03-01 | $17.73M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2010-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $6.97M derived: sum of 2 quarters · filed 2013-03-01 | $10.18M derived: sum of 3 quarters · filed 2013-03-01 | $13.62M 10-K · filed 2013-03-01 | ||||
| 2010-09-30 | $3.40M 10-Q · filed 2011-11-08 | $6.61M derived: sum of 2 quarters · filed 2011-11-08 | $10.05M 10-Q · filed 2011-11-08 | |||||
| 2010-06-30 | $3.21M 10-Q · filed 2011-08-05 | $6.66M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $13.67M 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |